Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial - McInnes, I B; Mease, P J; Kirkham, B; Kavanaugh, A; Ritchlin, C T; Rahman, P; van der Heijde, D; Landewé, R; Conaghan, P G; Gottlieb, A B; Richards, H; Pricop, L; Ligozio, G; Patekar, M; Mpofu, S; FUTURE 2 Study Group (Lancet, 2015)